Johnson & Johnson said on Friday that preliminary results from the initial testing phases of its Covid-19 vaccine showed patients developing strong antiviral loads, reports Reuters.
The single-shot vaccine, unlike drugs for the same purpose developed by competitors Moderna and Pfizer, showed that 98% of participants developed a response that conferred immunity to the disease 29 days after vaccination. The trials, under phases 1 and 2 of testing, included about 1,000 healthy adults in the USA. However, the low percentage of elderly people in the trials does not yet allow us to draw robust conclusions about the application of the vaccine in this risk group, remarks Reuters.
The company has already advanced with phase 3 of the trials, which will involve 60,000 participants. The results are expected to be available at the end of the year or early 2021. The results published this Friday have not been subject to peer review.
–
